Free

Midwest CEPAC Meeting: Acute Treatments for Migraine

Event Information

Share this event

Date and Time

Location

Location

Grand Ballroom, Sheraton Suites Chicago O'Hare

6501 Mannheim Road

Rosemont, IL 60018

View Map

Event description
ICER Public Meeting to Deliberate on the Comparative Clinical and Cost Effectiveness of Acute Treatments for Migraine

About this Event

The Midwest Comparative Effectiveness Public Advisory Council (CEPAC), a core program of the Institute for Clinical and Economic Review (ICER), will hold a public meeting on January 23, 2020 to consider the comparative clinical effectiveness and value of rimegepant (Biohaven), ubrogepant (Allergan), and lasmiditan (Eli Lilly) for migraine.

Migraine is a common, episodic cause of disabling headache often associated with nausea and sensitivity to light and sound. Approximately 40 million adults (12-15%) in the United States (US) have reported migraine or severe headaches.

A presentation of the evidence will be followed by a public comment period as well as deliberations and votes by the Midwest CEPAC. The votes will be followed by a policy roundtable discussion. This is ICER's third review of treatments for migraine; the first took place in July 2014, and the second in July 2018.

A list of key dates for stakeholder engagement opportunities and other important information associated with the review of treatments for migraine can be found on ICER's website at https://icer-review.org/topic/migraines/.

The public meeting will take place in the Grand Ballroom of the Sheraton Suites Chicago O'Hare

Share with friends

Date and Time

Location

Grand Ballroom, Sheraton Suites Chicago O'Hare

6501 Mannheim Road

Rosemont, IL 60018

View Map

Save This Event

Event Saved